{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T06:48:16Z","timestamp":1781765296500,"version":"3.54.5"},"reference-count":66,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Boehringer Ingelheim"},{"name":"Boehringer Ingelheim"},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinecjc.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.cjca.2019.02.009","type":"journal-article","created":{"date-parts":[[2019,2,21]],"date-time":"2019-02-21T22:38:24Z","timestamp":1550788704000},"page":"619-633","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Stroke Prevention, Evaluation of Bleeding Risk, and Anticoagulant Treatment Management in Atrial Fibrillation Contemporary International Guidelines"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1452-2478","authenticated-orcid":false,"given":"Marco","family":"Proietti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deirdre A.","family":"Lane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Boriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7566-1626","authenticated-orcid":false,"given":"Gregory Y.H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2019.02.009_bib1","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1160\/TH16-11-0876","article-title":"Stroke prevention in atrial fibrillation: past, present and future. Comparing the guidelines and practical decision-making","volume":"117","author":"Lip","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.cjca.2019.02.009_bib2","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2019.02.009_bib3","first-page":"899","article-title":"Increased use of oral anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 2015 in Denmark","volume":"38","author":"Gadsb\u00f8ll","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2019.02.009_bib4","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1016\/j.jacc.2017.03.540","article-title":"Influence of direct oral anticoagulants on rates of oral anticoagulation for atrial fibrillation","volume":"69","author":"Marzec","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2019.02.009_bib5","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1136\/heartjnl-2016-309832","article-title":"Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation","volume":"103","author":"Camm","year":"2017","journal-title":"Heart"},{"key":"10.1016\/j.cjca.2019.02.009_bib6","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/europace\/eux301","article-title":"Contemporary stroke prevention strategies in 11 096 European patients with atrial fibrillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) Long-Term General Registry","volume":"20","author":"Boriani","year":"2018","journal-title":"Europace"},{"key":"10.1016\/j.cjca.2019.02.009_bib7","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1161\/CIRCULATIONAHA.112.000491","article-title":"Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study","volume":"128","author":"Marijon","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2019.02.009_bib8","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.amjmed.2016.06.045","article-title":"Causes of death and influencing factors in patients with atrial fibrillation","volume":"129","author":"Fauchier","year":"2016","journal-title":"Am J Med"},{"key":"10.1016\/j.cjca.2019.02.009_bib9","first-page":"722","article-title":"\u201cReal-world\u201d atrial fibrillation management in Europe: observations from the 2-year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase","volume":"19","author":"Proietti","year":"2017","journal-title":"Europace"},{"key":"10.1016\/j.cjca.2019.02.009_bib10","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejim.2018.05.016","article-title":"Increased burden of comorbidities and risk of cardiovascular death in atrial fibrillation patients in Europe over ten years: a comparison between EORP-AF pilot and EHS-AF registries","volume":"55","author":"Proietti","year":"2018","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.cjca.2019.02.009_bib11","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/europace\/eux318","article-title":"Integrating new approaches to atrial fibrillation management: the 6th AFNET\/EHRA Consensus Conference","volume":"20","author":"Kotecha","year":"2018","journal-title":"Europace"},{"key":"10.1016\/j.cjca.2019.02.009_bib12","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1016\/S0140-6736(17)31072-3","article-title":"The future of atrial fibrillation management: integrated care and stratified therapy","volume":"390","author":"Kirchhof","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2019.02.009_bib13","first-page":"1170","article-title":"2016 Focused Update of the Canadian Cardiovascular Society guidelines for the management of atrial fibrillation","volume":"32","author":"Macle","year":"2016","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2019.02.009_bib14","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2019.02.009_bib15","first-page":"345","article-title":"2017 Consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation","volume":"33","author":"Chiang","year":"2017","journal-title":"J\u00a0Arrhythmia"},{"key":"10.1016\/j.cjca.2019.02.009_bib16","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.hlc.2018.06.1043","article-title":"National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018","volume":"27","author":"Brieger","year":"2018","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.cjca.2019.02.009_bib17","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.chest.2018.07.040","article-title":"Antithrombotic therapy for atrial fibrillation: CHEST Guideline and Expert Panel Report","volume":"154","author":"Lip","year":"2018","journal-title":"Chest"},{"key":"10.1016\/j.cjca.2019.02.009_bib18","first-page":"1371","article-title":"2018 Focused update of the Canadian Cardiovascular Society guidelines for the management of atrial fibrillation","volume":"34","author":"Andrade","year":"2018","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2019.02.009_bib19","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.4070\/kcj.2018.0339","article-title":"2018 Korean guideline of atrial fibrillation management","volume":"48","author":"Joung","year":"2018","journal-title":"Korean Circ J"},{"key":"10.1016\/j.cjca.2019.02.009_bib20","first-page":"27","article-title":"Canadian Cardiovascular Society atrial fibrillation guidelines 2010: implementing GRADE and achieving consensus","volume":"27","author":"Gillis","year":"2011","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2019.02.009_bib21","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1093\/eurheartj\/ehq278","article-title":"Guidelines for the management of atrial fibrillation","volume":"31","author":"Camm","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2019.02.009_bib22","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1093\/eurheartj\/ehs253","article-title":"2012 Focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association","volume":"33","author":"Camm","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2019.02.009_bib23","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","article-title":"Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation","volume":"285","author":"Gage","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2019.02.009_bib24","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1001\/jamainternmed.2013.11912","article-title":"Atrial fibrillation and the risk of myocardial infarction","volume":"174","author":"Soliman","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.cjca.2019.02.009_bib25","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1161\/CIRCULATIONAHA.114.014145","article-title":"Atrial fibrillation and risk of ST-segment-elevation versus non-ST-segment-elevation myocardial infarction: the Atherosclerosis Risk in Communities (ARIC) Study","volume":"131","author":"Soliman","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2019.02.009_bib26","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1160\/TH15-07-0612","article-title":"Ankle-Brachial Index and cardiovascular events in atrial fibrillation: the ARAPACIS study","volume":"115","author":"Violi","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.cjca.2019.02.009_bib27","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.jacc.2016.06.057","article-title":"Atrial fibrillation and thromboembolism in patients with chronic kidney disease","volume":"68","author":"Lau","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2019.02.009_bib28","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrcardio.2017.153","article-title":"The ABC pathway: an integrated approach to improve AF management","volume":"14","author":"Lip","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.cjca.2019.02.009_bib29","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1093\/eurheartj\/ehw007","article-title":"The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysis","volume":"37","author":"Ganesan","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2019.02.009_bib30","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1055\/s-0038-1676074","article-title":"Optimizing stroke and bleeding risk assessment in patients with atrial fibrillation: a balance of evidence, practicality and precision","volume":"118","author":"Proietti","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.cjca.2019.02.009_bib31","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1161\/CIRCULATIONAHA.116.022802","article-title":"Performance and validation of a novel biomarker-based stroke risk score for atrial fibrillation: clinical perspective","volume":"134","author":"Oldgren","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2019.02.009_bib32","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1055\/s-0038-1675400","article-title":"Predicting thromboembolic and bleeding event risk in patients with non-valvular atrial fibrillation: a systematic review","volume":"118","author":"Borre","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.cjca.2019.02.009_bib33","article-title":"Association between clinical risk scores and mortality in atrial fibrillation: systematic review and network meta-regression of 669,000 patients","author":"Proietti","year":"2018","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.cjca.2019.02.009_bib34","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1160\/TH09-02-0106","article-title":"Female gender is a risk factor for stroke and thromboembolism in atrial fibrillation patients","volume":"101","author":"Lane","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.cjca.2019.02.009_bib35","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2147\/IJWH.S45925","article-title":"Epidemiology, diagnosis, and management of atrial fibrillation in women","volume":"7","author":"Poli","year":"2015","journal-title":"Int J Womens Health"},{"key":"10.1016\/j.cjca.2019.02.009_bib36","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ijcard.2018.07.044","article-title":"Sex differences in stroke and major adverse clinical events in patients with atrial fibrillation: a systematic review and meta-analysis of 993,600 patients","volume":"269","author":"Marzona","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjca.2019.02.009_bib37","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1161\/CIRCULATIONAHA.117.029081","article-title":"Female sex is a risk modifier rather than a risk factor for stroke in atrial fibrillation: should we use a CHA2DS2-VA score rather than CHA2DS2-VASc?","volume":"137","author":"Nielsen","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2019.02.009_bib38","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.amjmed.2015.10.001","article-title":"Evaluation of the HAS-BLED, ATRIA and ORBIT bleeding risk scores in atrial fibrillation patients on warfarin","volume":"129","author":"Senoo","year":"2016","journal-title":"Am J Med"},{"key":"10.1016\/j.cjca.2019.02.009_bib39","doi-asserted-by":"crossref","first-page":"24376","DOI":"10.1038\/srep24376","article-title":"Major bleeding in patients with non-valvular atrial fibrillation: impact of time in therapeutic range on contemporary bleeding risk scores","volume":"6","author":"Proietti","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.cjca.2019.02.009_bib40","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1160\/TH17-07-0478","article-title":"Long-term bleeding risk prediction in \u201creal world\u201d patients with atrial fibrillation: comparison of the HAS-BLED and ABC-Bleeding risk scores. The Murcia Atrial Fibrillation Project","volume":"117","author":"Esteve-Pastor","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.cjca.2019.02.009_bib41","article-title":"Predicting bleeding events in anticoagulated patients with atrial fibrillation: a comparison between the HAS-BLED and GARFIELD-AF bleeding scores","volume":"7","author":"Proietti","year":"2018","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.cjca.2019.02.009_bib42","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1055\/s-0038-1636534","article-title":"Incident risk factors and major bleeding in patients with atrial fibrillation treated with oral anticoagulants: a comparison of baseline, follow-up and delta HAS-BLED scores with an approach focused on modifiable bleeding risk factors","volume":"118","author":"Chao","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.cjca.2019.02.009_bib43","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1160\/TH17-10-0710","article-title":"Assessing bleeding risk in atrial fibrillation patients: comparing a bleeding risk score based only on modifiable bleeding risk factors against the HAS-BLED score. The AMADEUS trial","volume":"117","author":"Esteve-Pastor","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.cjca.2019.02.009_bib44","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1160\/TH16-03-0203","article-title":"Dabigatran in real-world atrial fibrillation. Meta-analysis of observational comparison studies with vitamin K antagonists","volume":"116","author":"Carmo","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.cjca.2019.02.009_bib45","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1161\/STROKEAHA.116.016275","article-title":"Rivaroxaban versus dabigatran or warfarin in real-world studies of stroke prevention in atrial fibrillation","volume":"48","author":"Bai","year":"2017","journal-title":"Stroke"},{"key":"10.1016\/j.cjca.2019.02.009_bib46","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1161\/STROKEAHA.117.018395","article-title":"Real-world use of apixaban for stroke prevention in atrial fibrillation: a systematic review and meta-analysis","volume":"49","author":"Proietti","year":"2018","journal-title":"Stroke"},{"key":"10.1016\/j.cjca.2019.02.009_bib47","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.hrthm.2017.11.026","article-title":"Use of the SAMe-TT 2 R 2 score to predict anticoagulation control in atrial fibrillation and venous thromboembolism patients receiving vitamin K antagonists: a review","volume":"15","author":"Zulkifly","year":"2018","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.cjca.2019.02.009_bib48","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2019.02.009_bib49","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ahj.2017.05.016","article-title":"Time in therapeutic range and major adverse outcomes in atrial fibrillation patients undergoing percutaneous coronary intervention: the Atrial Fibrillation Undergoing Coronary Artery Stenting (AFCAS) registry","volume":"190","author":"Proietti","year":"2017","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2019.02.009_bib50","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/europace\/euy174","volume":"21","author":"Lip","year":"2019","journal-title":"Europace"},{"key":"10.1016\/j.cjca.2019.02.009_bib51","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2019.02.009_bib52","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2019.02.009_bib53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186449","article-title":"Antithrombotic therapy strategies for atrial fibrillation patients undergoing percutaneous coronary intervention: a systematic review and network meta-analysis","volume":"12","author":"Gong","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.cjca.2019.02.009_bib54","doi-asserted-by":"crossref","DOI":"10.1111\/1755-5922.12457","article-title":"Safety and efficacy of nonvitamin K antagonist oral anticoagulants during catheter ablation of atrial fibrillation: a systematic review and meta-analysis","volume":"36","author":"Ge","year":"2018","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.cjca.2019.02.009_bib55","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ijcard.2018.06.024","article-title":"A\u00a0meta-analysis of randomized controlled trials of uninterrupted periprocedural anticoagulation strategy in patients undergoing atrial fibrillation catheter ablation","volume":"270","author":"Zhao","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjca.2019.02.009_bib56","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/s11239-018-1622-5","article-title":"Direct oral anti-coagulants compared to vitamin-K antagonists in cardioversion of atrial fibrillation: an updated meta-analysis","volume":"45","author":"Brunetti","year":"2018","journal-title":"J\u00a0Thromb Thrombolysis"},{"key":"10.1016\/j.cjca.2019.02.009_bib57","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ahj.2017.04.008","article-title":"Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial","volume":"189","author":"Lopes","year":"2017","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2019.02.009_bib58","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ahj.2017.04.015","article-title":"Probing oral anticoagulation in patients with atrial high rate episodes: rationale and design of the non-vitamin K antagonist oral anticoagulants in patients with atrial high rate episodes (NOAH-AFNET 6) trial","volume":"190","author":"Kirchhof","year":"2017","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2019.02.009_bib59","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1136\/heartjnl-2016-310952","article-title":"Integrated care in atrial fibrillation: a systematic review and meta-analysis","volume":"103","author":"Gallagher","year":"2017","journal-title":"Heart"},{"key":"10.1016\/j.cjca.2019.02.009_bib60","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.amjmed.2018.06.012","article-title":"Improved outcomes by integrated care of anticoagulated patients with atrial fibrillation using the simple ABC (Atrial Fibrillation Better Care) pathway","volume":"131","author":"Proietti","year":"2018","journal-title":"Am J Med"},{"key":"10.1016\/j.cjca.2019.02.009_bib61","author":"Pastori"},{"key":"10.1016\/j.cjca.2019.02.009_bib62","author":"Pastori"},{"key":"10.1016\/j.cjca.2019.02.009_bib63","first-page":"125","article-title":"Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate\/rhythm control","volume":"28","author":"Skanes","year":"2012","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2019.02.009_bib64","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/jth.12177","article-title":"The impact of atherosclerotic vascular disease in predicting a stroke, thromboembolism and mortality in atrial fibrillation patients: a systematic review","volume":"11","author":"Anandasundaram","year":"2013","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.cjca.2019.02.009_bib65","first-page":"2162","article-title":"Coronary artery disease is independent risk factor for stroke among patients with atrial fibrillation","volume":"118","author":"Steensig","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2019.02.009_bib66","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1055\/s-0038-1675401","article-title":"Should the presence or extent of coronary artery disease be quantified in the CHA2DS2-VASc score in atrial fibrillation? A report from the Western Denmark Heart Registry","volume":"118","author":"Steensig","year":"2018","journal-title":"Thromb Haemost"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X19301163?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X19301163?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:40:58Z","timestamp":1760107258000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X19301163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":66,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S0828282X19301163"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2019.02.009","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stroke Prevention, Evaluation of Bleeding Risk, and Anticoagulant Treatment Management in Atrial Fibrillation Contemporary International Guidelines","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2019.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}